MedImmune Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:MedImmune Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014023
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MedImmune Ltd (MedImmune), formerly Cambridge Antibody Technology Ltd, is a subsidiary of AstraZeneca Plc, is a research and development company that develops and commercializes small molecule and biologic prescription medicines for the prevention of respiratory tract disease caused by respiratory syncytial virus. The company’s products include synagis, a monoclonal antibody; flumist, a quadrivalent influenza vaccine; and amifostine. It concentrates in therapeutic areas such as respiratory, oncology, inflammation and autoimmune, and cardiovascular and metabolic disease. MedImmune partners with other pharma companies to develop new products. The company operates its facilities in the US, the UK and the Netherlands. MedImmune is headquartered in Cambridge, the UK.

MedImmune Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MedImmune Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MedImmune Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MedImmune Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MedImmune Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
MedImmune Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MedImmune Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
MedImmune Acquires Patent Rights and Technologies from Allozyne 10
Partnerships 11
Celgene Enters into Co-Development Agreement with MedImmune 11
MedImmune Enters Research Agreement With University of Texas MD Anderson 12
Licensing Agreements 13
MedImmune Enters into Licensing Agreement with Omnis Pharma 13
Evotec Expands Licensing Agreement With MedImmune For Diabetes And Beta Cell Regeneration 14
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 15
MedImmune Ltd – Key Competitors 16
MedImmune Ltd – Key Employees 17
MedImmune Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Corporate Communications 19
Nov 21, 2016: AstraZeneca’s MedImmune completes licensing agreement with Allergan for MEDI2070 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
MedImmune Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 2
MedImmune Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
MedImmune Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
MedImmune Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
MedImmune Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
MedImmune Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MedImmune Acquires Patent Rights and Technologies from Allozyne 10
Celgene Enters into Co-Development Agreement with MedImmune 11
MedImmune Enters Research Agreement With University of Texas MD Anderson 12
MedImmune Enters into Licensing Agreement with Omnis Pharma 13
Evotec Expands Licensing Agreement With MedImmune For Diabetes And Beta Cell Regeneration 14
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 15
MedImmune Ltd, Key Competitors 16
MedImmune Ltd, Key Employees 17
MedImmune Ltd, Other Locations 18

★海外企業調査レポート[MedImmune Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Impact Developer & Contractor SA:企業の戦略・SWOT・財務情報
    Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report Summary Impact Developer & Contractor SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Accredo Health Group Inc:企業の戦略的SWOT分析
    Accredo Health Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Fujirebio Europe NV:企業の戦略的SWOT分析
    Fujirebio Europe NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • View Inc:電力:M&Aディール及び事業提携情報
    Summary View Inc (View), formerly Soladigm, Inc. is a clean technology company that offers smart glass systems. The company’s View Dynamic Glass controls light and heat entering the building. View Dynamic Glass uses intelligent engine that adapts to the environment, responds to users’ preferences an …
  • Aeon Delight Co Ltd:企業の戦略・SWOT・財務情報
    Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Himatsingka Seide Ltd.:戦略・SWOT・企業財務分析
    Himatsingka Seide Ltd. - Strategy, SWOT and Corporate Finance Report Summary Himatsingka Seide Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Sartorius Stedim Biotech SA (DIM):企業の財務・戦略的SWOT分析
    Sartorius Stedim Biotech SA (DIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Abeome Corp-製薬・医療分野:企業M&A・提携分析
    Summary Abeome Corp (Abeome) is a biotechnology company that discovers diagnostic monoclonal antibodies and therapeutic antibodies. The company's pipeline components include PCSK9 to treat hypercholesterolemia; IL-17A to treat psoriasis and inflammation diseases, IL-17F to treat autoimmune diseases, …
  • Merck KGaA (MRK):企業の財務・戦略的SWOT分析
    Merck KGaA (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Malayan Flour Mills Berhad:企業の戦略・SWOT・財務分析
    Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report Summary Malayan Flour Mills Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • EyeGate Pharmaceuticals Inc (EYEG):企業の財務・戦略的SWOT分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s proprietary technology EyeGate II delivery system, utilizes transscleral iontop …
  • Cellumed Co Ltd (049180):医療機器:M&Aディール及び事業提携情報
    Summary Cellumed Co Ltd (Cellumed), formerly Korea Bone Bank Inc is a biotechnology company that develops bone graft substitution based on human tissue graft. The company offers allograft tissue products such as bio-clearant, a clearant process that treats tissues with patented chemicals and sterili …
  • Enerflex Ltd (EFX):企業の財務・戦略的SWOT分析
    Enerflex Ltd (EFX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Heijmans NV:企業の戦略・SWOT・財務情報
    Heijmans NV - Strategy, SWOT and Corporate Finance Report Summary Heijmans NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Energy Transfer Partners, L.P.:企業の戦略・SWOT・財務情報
    Energy Transfer Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Energy Transfer Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Battelle Memorial Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Battelle Memorial Institute (Battelle) is a nonprofit research and development (R&D) organization. It carries out discovery, design, development, and manufacture of products, and renders its services to government and commercial customers. The institute manages national laboratories and main …
  • Cavco Industries Inc:企業の戦略・SWOT・財務情報
    Cavco Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Cavco Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Penumbra Inc (PEN):医療機器:M&Aディール及び事業提携情報
    Summary Penumbra Inc (Penumbra) is a medical device company that designs, develops, manufactures and markets neuro devices and peripheral devices. The company’s neurovascular mechanical thrombectomy systems include revascularization device, reperfusion catheters, distal delivery catheters, neuro eva …
  • Haoma Mining NL:企業の戦略・SWOT・財務情報
    Haoma Mining NL - Strategy, SWOT and Corporate Finance Report Summary Haoma Mining NL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Oxford BioMedica Plc (OXB):製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford BioMedica plc (Oxford Biomedica) is a gene and cell therapy company that focuses on developing novel treatments for serious diseases. The company along with its subsidiaries has developed LentiVector, a sector leading lentiviral vector delivery platform. It has also built a platform o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆